RxDoctor Payments Data

Ashruta Patel, DO

Internal Medicine · Lancaster, CANPI 1346745262

Payments from drug & device makers

$1,453in general payments, 2019–2025

Across 40 payments — averaging $36.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$366
  • AbbVie$316
  • Lilly USA, LLC$217
  • Boehringer Ingelheim$173
  • Bayer$157
  • Viiv Healthcare Company$125
  • plus $99 from 4 others

What the payments were for

  • Food & beverage$1,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$454
Medicare patients
31
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide202$196,452
JardianceEmpagliflozin63$79,387
MounjaroTirzepatide75$76,679
SynjardyEmpagliflozin/Metformin Hcl52$75,166
RybelsusSemaglutide44$72,418
Synjardy XrEmpagliflozin/Metformin Hcl41$66,846
EliquisApixaban40$30,373
Tresiba Flextouch U-100Insulin Degludec43$26,216
JanuviaSitagliptin Phosphate15$22,308
FarxigaDapagliflozin Propanediol18$19,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,691
Albuterol Sulfate HfaAlbuterol Sulfate158$11,042
Combivent RespimatIpratropium/Albuterol Sulfate12$5,721
Tolterodine Tartrate ErTolterodine Tartrate26$5,463
Atrovent HfaIpratropium Bromide11$4,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$366$268,870246 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Combivent Respimat$173$227,119168 claims
Lilly USA, LLCMounjaro$217$76,67975 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →